Affiliation: Fox Chase Cancer Center
- Pathology of Ovarian Neoplasms in Genetically Modified MiceAlexander Y Nikitin
Department of Biomedical Sciences, Cornell University, T2 014A VRT, Campus Road, Ithaca, New York 14853
Comp Med 54:26-8. 2004
- Recombinant human Mullerian inhibiting substance inhibits long-term growth of MIS type II receptor-directed transgenic mouse ovarian cancers in vivoRafael Pieretti-Vanmarcke
Pediatric Surgical Research Laboratories, Department of Surgery, Massachusetts General Hospital, Boston, MA 02114, USA
Clin Cancer Res 12:1593-8. 2006..We examined whether rhMIS as a novel, nontoxic, naturally occurring growth inhibitor can be an effective anticancer drug in long-term studies in vivo against allograft tumors that recapitulate human ovarian carcinoma...
- Mullerian Inhibiting Substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancerRafael Pieretti-Vanmarcke
Pediatric Surgical Research Laboratories, Department of Surgery, Massachusetts General Hospital Harvard Medical School, Boston, MA 02114, USA
Proc Natl Acad Sci U S A 103:17426-31. 2006..These assays and statistical analyses could be useful in selecting rhMIS and chemotherapeutic agent combinations that enhance clinical efficacy and reduce toxicity...
- Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancerDenise C Connolly
Ovarian Cancer Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
Cancer Res 63:1389-97. 2003....
- Activation of cancer-specific gene expression by the survivin promoterRudi Bao
Ovarian Cancer Program, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
J Natl Cancer Inst 94:522-8. 2002..To investigate whether the survivin promoter controls cancer cell-specific gene expression, we determined whether the survivin gene promoter could regulate reporter gene expression in cancer cell lines and xenografts...
- Focus on epithelial ovarian cancerRobert F Ozols
Fox Chase Cancer Center, Philadelphia, PA 19111, USA
Cancer Cell 5:19-24. 2004
- Cyclooxygenase-1 is overexpressed in multiple genetically engineered mouse models of epithelial ovarian cancerTakiko Daikoku
Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee 37232, USA
Cancer Res 66:2527-31. 2006..The results provide further evidence that Cox-1 overexpression is common in various models of EOC. Thus, Cox-1 serves as a potential marker of EOC and is a possible target for the prevention and/or treatment of this deadly disease...
- RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancerSeiji Mabuchi
Human Genetics Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
Cancer Res 67:2408-13. 2007....
- Magnetic resonance imaging for detection and determination of tumor volume in a genetically engineered mouse model of ovarian cancerHARVEY HENSLEY
Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
Cancer Biol Ther 6:1717-25. 2007..Our results demonstrate that MRI is well tolerated and can be repeated in serial imaging studies, permitting quantitative analysis of tumor growth and progression and response to therapeutic interventions...
- The Role of HEF1 in Ovarian Cancer Development, Progression, and MetastasisDenise C Connolly; Fiscal Year: 2010..These studies may reveal several important molecular pathways regulated by HEF1 that can be targeted for treatment of ovarian cancer patients. ..